ライムボレリア症ワクチンのグローバル市場機会分析(MarketVIEW: Lyme Borreliosis vaccines)...市場調査レポートについてご紹介

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

★目次PDFファイル⇒http://h-and-i.main.jp/market-report/Vaczine/VAMV024.pdf

****This product is composed of a model and summary presentation

【Contents – Summary presentation (MS PowerPoint based)】

Author’s note
Executive Summary
Lyme Borreliosis vaccines: available market EU+US ($ 000s) to 2035
Lyme Borreliosis vaccines: available market per country ($ 000s) to 2035
Lyme Borreliosis vaccines: predicted demand EU+US (Doses 000s) to 2035
Lyme Borreliosis vaccines: predicted revenues per competitor to 2035
Lyme Borreliosis: disease background
Lyme Borreliosis: latest disease trends and dynamics
Lyme Borreliosis: background
Lyme borreliosis: vector lifecycle and distribution
Global vector distribution
Ixodes ricinus distribution, Europe, March 2013
Genospecies distribution
Distribution of Borrelia genospecies in Europe
Clinical features
Clinical features of confirmed LB cases, US, 2001-10
Comparison of clinical features of LB, US and Europe.
Diagnosis and treatment
Age, sex and racial distribution
Confirmed LB cases by age and sex, US, 2001-2010
Epidemiology – US
Confirmed and probable LB cases, US, 2003-2012
Confirmed cases of LB, US, 2001 and 2012
LB incidence rate by state, confirmed cases, 2012.
Focus on southern New Hampshire, 2012
Epidemiology – EU
Annual number of LB cases per country, Europe
Lyme borreliosis: vaccine history and development
Vaccines: competitive landscape
Lyme Borreliosis vaccines: target product profiles
Baxter’s LB vaccine
Baxter’s LB vaccine: frequency of local and systemic reactions
Lyme Borreliosis vaccines: GSK’s LYMErix
Negative public perception of LYMErix
Challenges to gaining US market acceptance
Cost-effectiveness of Lyme disease vaccination
Lyme borreliosis: modelling commercial potential
Methodology
Countries/regions included in the model
Major commercial model assumptions
Commercial model assumptions by country
Appendix I – Lyme borreliosis: focused country overview
Austria
Belgium
Croatia
Czech Republic
Estonia
Finland
France
Germany
Hungary
Italy
Latvia
Lithuania
The Netherlands
Norway
Poland
Slovakia
Slovenia
Sweden
Switzerland
Other countries
Appendix II – Lyme borreliosis: country risk maps
US risk areas
Belgium risk areas
Croatia risk areas
France risk areas
Germany risk areas
Hungary risk areas
Finland risk areas
Bibliography
About VacZine Analytics
Disclaimer

※PAGES: 105 MS PowerPoint slides, fully referenced/sourced. Available in .pdf form

【Contents – Vaccine demand model (MS Excel-based)】

Title sheet
Total charts
Charts value
Charts volume
Value summary (TOTAL MARKET)
Volume summary (TOTAL MARKET)
US (base) adult
US (base) infant
Austria (base) adult
Austria (base) infant
Belgium (base) adult
Belgium (base) infant
Croatia (base) adult
Croatia (base) infant
Czech (base) adult
Czech (base) infant
Estonia (base) adult
Estonia (base) infant
Finland (base) adult
Finland (base) infant
France (base) adult
France (base) infant
Germany (base) adult
Germany (base) infant
Hungary (base) adult
Hungary (base) infant
Lithuania (base) adult
Lithuania (base) infant
Latvia (base) adult
Latvia (base) infant
Holland (base) adult
Holland (base) infant
Poland (base) adult
Poland (base) infant
Slovakia (base) adult
Slovakia (base) infant
Slovenia (base) adult
Slovenia (base) infant
Sweden (base) adult
Sweden (base) infant
Switzerland (base) adult
Switzerland (base) infant
Source material
Incidence rates (US)
Incidence rates (EU)
Populations at risk
Genospecies

※WORKSHEETS: ~56


【レポート販売概要】

■ タイトル:ライムボレリア症ワクチンのグローバル市場機会分析(MarketVIEW: Lyme Borreliosis vaccines)
■ 発行日:2014年4月
■ 調査会社:VacZine Analytics
■ 商品コード:VAMV024
■ 調査対象地域:グローバル
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。